EcoDrugPlus

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSUMAG00000017060
Gene Symbol: HTR2B
4 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSUMAG00000022914
Gene Symbol: HTR2C
4 Cross references
223 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSUMAG00000003795
Gene Symbol: HTR3B
4 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 3c-Like

Ensembl ID : ENSUMAG00000006476
Gene Symbol: LOC103676087
3 Cross references
57 Possible Orthologues:

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSUMAG00000006439
Gene Symbol: HTR3E
4 Cross references
38 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSUMAG00000005494
Gene Symbol: HTR4
2 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSUMAG00000014544
Gene Symbol: HTR5A
4 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSUMAG00000000952
Gene Symbol: HTR7
2 Cross references
219 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSUMAG00000008085
Gene Symbol: ARAF
1 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSUMAG00000018694
Gene Symbol: ABL1
4 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSUMAG00000003653
Gene Symbol: ADAM17
4 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSUMAG00000014840
Gene Symbol: ADAMTS5
4 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).